In this regard, differences in the KYNU expression and activity within the triple negative and HER2-enriched breast cancer samples have been reported and a predictive model for triple negative and non-triple negative breast cancer diagnosis has been proposed based on the KYNU activity markers measured on the patient serum [60]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.